CROI 2017 Program and Information

Program and Agenda

114LB REAL PROGRESS IN THE HIV EPIDEMIC: PHIA FINDINGS FROM ZIMBABWE, MALAWI, AND ZAMBIA Jessica E. Justman 1 , David Hoos 1 , Graham Kalton 2 , Rose Nyirenda 3 , Crispin Moyo 4 , Owen Mugurungi 5 , Andrew Voetsch 6 , Hetal Patel 6 , Laura Porter 6 , for the PHIA Project Teams for Malawi, Zambia and Zimbabwe 1 ICAP at Columbia Univ, New York, NY, USA, 2 Westat, Inc., Rockville, MD, USA, 3 Government of Malawi Ministry of Hlth, Lilongwe, Malawi, 4 Government of Zambia Ministry of Hlth, Lusaka, Zambia, 5 Ministry of Hlth and Child Welfare, Zimbabwe, Harare, Zimbabwe, 6 CDC, Atlanta, GA, USA 115 STRATEGIES TO ACHIEVE 90-90-90: MODELING INSIGHTS FROM ZIMBABWE Jack Olney , Jeffrey Eaton, Ellen McRobie, Timothy B. Hallett Imperial Coll London, London, UK 116 HIV CASCADE OF CARE INTERVENTIONS IN KENYA: CLINICAL IMPACT AND COST-EFFECTIVENESS Liem Binh Luong Nguyen 1 , Yazdan Yazdanpanah 1 , David Maman 2 , Stephen Wanjala 3 , Alexandra Vandenbulcke 4 , Elisabeth Szumilin 4 , William Hennequin 4 , Robert Parker 5 , Pierre Mendiharat 4 , Kenneth Freedberg 5 1 INSERM, Paris, France, 2 Epicentre, Cape Town, South Africa, 3 MSF, Nairobi, Kenya, 4 MSF, Paris, France, 5 Massachusetts General Hosp, Boston, MA, USA 117 A RANDOMIZED TRIAL OF READY-TO-USE SUPPLEMENTARY FOOD AT ART INITIATION IN AFRICA Jane E. Mallewa 1 , Alexander J. Szubert 2 , Jay Berkley 3 , Sanele Nkomani 4 , Abraham Siika 5 , Peter Mugyenyi 5 , Andrew Prendergast 6 , Sarah Walker 2 , Diana Gibb 2 , for the REALITY Trial Team 1 Malawi–Liverpool–Wellcome Trust Clinical Rsr Prog, Blantyre, Malawi, 2 Univ Coll London, London, UK, 3 KEMRI Wellcome Trust Rsr Prog, Kilifi, Kenya, 4 Univ of Zimbabwe Clinical Rsr Cntr, Harare, Zimbabwe, 5 Moi Univ, Eldoret, Kenya, 6 Queen Mary Univ of London, London, UK Oral Abstract Moderators Ann Chahroudi , Emory University School of Medicine, Atlanta, GA, USA Davey Smith , Univ of California, San Diego, La Jolla, CA, USA 118 TLR7 AGONIST GS-9620 INCREASES IMMUNE-MEDIATED CLEARANCE OF HIV-INFECTED CELLS Alivelu Irrinki 1 , Angela Tsai 1 , Jasmine Kaur 1 , Jay Lalezari 2 , Tomas Cihlar 1 , George Kukolj 1 , Derek D. Sloan 3 , Jeffrey Murry 1 1 Gilead Scis, Inc, Foster City, CA, USA, 2 Quest Clinical Rsr, San Francisco, CA, USA, 3 Agenovir, South San Francisco, CA, USA 119LB VIRAL CONTROL INDUCED BY HIVCONSV VACCINES & ROMIDEPSIN IN EARLY TREATED INDIVIDUALS Beatriz Mothe 1 , José Moltó 2 , Christian Manzardo 3 , Josep Coll 1 , Maria C. Puertas 1 , Javier Martinez-Picado 1 , Tomas Hanke 4 , Bonaventura Clotet 1 , Christian Brander 1 , for the BCN02-Romi Study Group 11:00 11:15 11:30 11:45 10:00 10:15 Oral Abstract O-11 HIV PERSISTENCE AND REACTIVATION Room 6 E 10:00 AM - 12:00 PM

Oral Sessions • Thursday

1 IrsiCaixa AIDS Rsr Inst, Badalona, Spain, 2 Fundació Lluita Contra la Sida, Badalona, Spain, 3 Univ of Barcelona, Barcelona, Spain, 4 The Jenner Inst, Oxford, UK

CROI 2017 61